BioBiz Buzz – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

BioBiz Buzz

https://biobizbuzz.com/

News

Frequency: 1 episode/1d. Total Eps: 28

BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries.

Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences.

Disclaimer

https://biobizbuzz.com/disclaimer/

Read moreCollapse

Site

RSS

Apple

Data updated on 04/07/2026

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

https://biobizbuzz.com/disclaimer/
4 shares
https://biobizbuzz.com/contact/
3 shares
https://biobizbuzz.com/subscribe/
3 shares

https://bsky.app/profile/biobizbuzz.com
3 shares

https://www.linkedin.com/company/biobizbuzz/
3 shares

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

Good

Score global : 73%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Rewriting the Future of Rare Cardiovascular Disease Through Epigenetic Innovation

Season 1 · Episode 3

Friday, May 2, 2025 • Duration 23:29

In this episode of BioBiz Buzz, your host Mike Ward sits down with Sten R. Sörensen, CEO of Cereno Scientific, to explore how the Swedish biotech is pioneering a new era in rare cardiovascular and pulmonary disease therapeutics.

Cereno’s lead candidates, CS1 and CS014, leverage epigenetic modulation through histone deacetylase inhibition (HDACi) to address the root causes of diseases like pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), aiming to reverse pathological remodeling and prevent thrombosis-without the bleeding risks of traditional therapies.

Sörensen discusses the company’s strategic pivot to rare diseases, the science behind their innovative pipeline, and the impact of recent SEK250 million financing on accelerating clinical programs. The conversation also highlights Cereno’s approach to partnerships, regulatory milestones, and the transformative potential of targeting gene expression in cardiovascular drug development.

Tune in for a deep dive into the future of disease-modifying therapies and the milestones shaping Cereno’s journey in 2025

● Feedback

● Subscribe (Get notified when new episodes are available. NO marketing!)

● Disclaimer

● LinkedIn

● Bluesky

Read moreCollapse

Breaking Barriers in Sexual Health: Dicot Pharma’s LIB-01 and the Future of ED Treatment

Season 1 · Episode 2

Friday, May 2, 2025 • Duration 14:23

This episode of BioBiz Buzz spotlights the rapidly growing global markets for erectile dysfunction (ED) and premature ejaculation (PE), conditions impacting over 500 million men worldwide.

Your host Mike Ward interviews Elin Trampe, CEO of Dicot Pharma, who discusses the company’s innovative drug candidate, LIB-01.

Unlike conventional therapies, LIB-01 introduces a novel mechanism of action and offers a significantly longer efficacy window, 28 days after a brief 3-day dosing according to exploratory data in the phase 1 trial, potentially transforming the standard of care for both ED and PE.

Trampe shares insights on the drug’s clinical progress, the company’s strategic partnerships, and efforts to reduce the stigma surrounding sexual health.

● Feedback

● Subscribe (Get notified when new episodes are available. NO marketing!)

● Disclaimer

● LinkedIn

● Bluesky

Read moreCollapse

CRISPR Unleashed: How Caszyme Is Redefining the Future of Gene Editing

Season 1 · Episode 1

Thursday, May 1, 2025 • Duration 19:54

This episode of BioBiz Buzz features Dr. Monika Paule, CEO and co-founder of Caszyme, a pioneering Lithuanian biotech company at the forefront of CRISPR-Cas technology.

Your host Mike Ward explores how Caszyme is expanding the boundaries of gene editing through novel enzyme discovery, delivery optimization, and strategic collaborations, enabling breakthroughs in therapeutics, diagnostics, and sustainable agriculture.

Dr. Paule discusses Caszyme’s unique approach to engineering smaller, more versatile Cas enzymes, their impact on treating genetic diseases, and the challenges of translating cutting-edge science into clinical and commercial success.

The conversation also addresses the importance of diversity in biotech leadership and Caszyme’s vision for a more inclusive and sustainable future, highlighting the transformative potential and ongoing challenges of the CRISPR revolution.

● Feedback

● Subscribe (Get notified when new episodes are available. NO marketing!)

● Disclaimer

● LinkedIn

● Bluesky

Read moreCollapse

BioBiz Buzz – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

BioBiz Buzz – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

Other3

Blueskye1

LinkedIn1

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Other3

Blueskye1

LinkedIn1

Apple Podcasts

Spotify